Naslov
Unusual marker expression in acute leukemia is associated with low remission rate

Autori
Batinić, Drago ; Mrsić, Sanja ; Mrsić, Mirando ; Boban, Dubravka ; Nemet, Damir ; Užarević, Branka ; Bogdanić, Vinko ; Aurer, Igor ; Radman, Ivo ; Marković-Glamočak, Mirjana ; Sučić, Mirna ; Sertić, Dubravka ; Pisk, Mirta ; Marušić, Matko ; Stavljenić-Rukavina, Ana ; Labar, Boris

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
The Second Croatian Congress in Human Genetics Paediatr Croat 1998 42 Suppl 3 / - Zagreb : Klinika za pedijatriju, Zagreb, 1998, 39-39

Skup
The Second Croatian Congress in Human Genetics

Mjesto i datum
Zagreb, Hrvatska, 21.10.1998. - 24.10.1998

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
acute leukemia ; biphenotypic ; prognosis

Sažetak
From 1988. to 1998. a total of 40 patients with acute leukaemia (AL) presented with unusual blast immunophenotype. There were 12 females (30%) and 28 males (70%), aged 20-60 (median 41). The FAB types were ALL (10), ALL-L1 (4), undifferentiated AL (AUL, 18) and AML-M1 (8). The basic panel of reagents run on all patients included CD2, CD5, CD10, CD19, CD13, CD33, Cdw65, HLA-DR and CD34, followed by various second-line linegae-associated reagents. Cytogenetic abnormalities were found in 16 of 40 patients with unusual blast-immunophenotype. Match-pair analysis was conducted according to age, sex, FAB, cytogenetic abnormalities and number of WBC at diagnosis. Two control groups were established: AML (n=51) and ALL (n=26). Remission rate for patients with unusual blast marker expression was 48%, which was in contrast to AML (74%) and ALL (68%) (p<0.02). Median remission duration for AL with unusual blast immunophenotype was 6 months (3-15), for AML 18 months (3-42) and for ALL 16 months (3-38) (p<0.02). Probability of relapse was 75% for unusual AL, 42% for AML and 52% for ALL (p<0.03, long rank analysis). However, the probability of leukemia free survival was not different among three studied groups of patients. In conclusion, patients who presented with AL with unusual blast-immunophenotype had significantly lower remission rate and higher relapse rate.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti, Farmacija

POVEZANOST RADA